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Vemurafenib is a first-in-class, small molecule B-Raf kinase 
inhibitor for the treatment of patients with unresectable or meta-
static melanoma carrying the BRAFV600E mutation, commer-
cially available since 2011. A  general phototoxic potential was 
identified early during development; however, based on results of 
an animal study in hairless rats, it was concluded that there would 
exist no relevant risk for humans. Surprisingly, signs of clinical 
photosensitivity were reported in many patients during clinical 
development. Therefore, it became a fundamental question to 
understand this discrepancy. An established mouse model (oral 
UV-Local Lymph Node Assay, UV-LLNA) for the assessment of 
in vivo photosafety was used to investigate the impact of formula-
tions, dose levels, duration of treatment, and timing of irradiation. 
Moreover, a basic pharmacokinetic profile was established within 
the same mouse strain. We were able to demonstrate dose- and 
time-dependent phototoxicity of vemurafenib using commercially 
available tablets (stabilized amorphous material). The lowest 
phototoxic dose was 350 mg/kg administrated for 3 consecutive 
days followed by exposure to UV-visible irradiation at a UVA-
normalized dose of 10 J/cm2. In comparison, pure vemurafenib, 
which easily forms crystalline variants and is known to have poor 
bioavailability, was tested at 350 mg/kg, and no signs of photo-
toxicity could be seen. The most apparent difference between the 
early study in hairless rats and this study in mice was the spectral 
range of the irradiation light source (350–400 nm vs 320–700 nm). 
Because vemurafenib does not absorb sufficiently light above 
350 nm, this difference can easily explain the negative earlier 
study result in hairless rats.
Key Words: phototoxicity; photosensitivity; photosafety; 
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Vemurafenib is a first-in-class, small molecule B-Raf kinase 
inhibitor for the treatment of patients with unresectable or met-
astatic melanoma carrying the BRAFV600E mutation. It was 
approved in 2011 in the United States (FDA review, 2011), in 
the European Union (CHMP review, 2011), and in Switzerland.
Although a general phototoxic potential was identified early 
for this compound (based on UV-vis spectra and in vitro 3T3 
Neutral Red Uptake (NRU) phototoxicity data), the initial con-
clusion was made that no relevant human risk would exist. 
Apparently, this was driven by the results of an animal study, 
suggesting that no increased sensitivity to light could be induced 
(CHMP review, 2011; FDA review, 2011). Surprisingly, signs 
of clinical photosensitivity were reported in 42% of patients 
included in the phase I trial extension cohort. Similarly, during 
phase II and phase III, 52% and 30% of vemurafenib-treated 
patients were affected, respectively (Chapman et  al., 2011; 
Flaherty et  al., 2010; Lacouture et  al., 2013). The findings 
included severe (grade 2 and 3) sunburn-like reactions, which 
occurred even after exposure to sun light through window glass 
(eg, while driving a car), and thus had a significant impact on 
the quality of life. Later, Dummer et al. (2012) confirmed that 
the minimal erythema dose (MED) in patients receiving vemu-
rafenib was markedly reduced in the UVA range, whereas the 
UVB-dependent MED remained unchanged compared with 
untreated subjects. Therefore, we felt encouraged to understand 
the reasons behind this situation that a clinically relevant strong 
phototoxicity had gone undetected preclinically. In particular, it 
was of great interest to learn how such potentially “false nega-
tive” animal studies can be avoided in the future.
In this study, we utilized an established mouse model for the 
assessment of in vivo photosafety. This model is based on a 
modified (cell count-based) UV-LLNA in albino Balb/c mice 
as described by Ulrich et al. (2001). However, with oral admin-
istration, the main endpoint of this model is acute phototoxicity 
rather than (photo)-contact allergy. A similar approach was also 
described by Vohr et al. (2000). Typically, mice were treated 
for 3 days including daily exposure to simulated sunlight. The 
light source used provided a reasonable coverage of the UVA 
and visible light range, whereas highly cytotoxic UVB irra-
diation was attenuated in order to not limit the overall irradia-
tion (which was normalized to a UVA dose of 10 J/cm2 UVA). 
Any skin reactions (mainly erythema seen at the ears) were 
recorded during these days. Subsequently, edema (by meas-
uring ear weight) and markers of local inflammation (weight 
and cell count of the ear-draining auricular lymph nodes) were 
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assessed. Historically, a treatment period of 3  days has been 
used to allow for sufficient activation of the local lymph nodes. 
However, in the context of photosafety evaluation of systemi-
cally administered drugs, the repeated-dose protocol does also 
ensure sufficient distribution of compounds to skin.
During clinical development of vemurafenib, it became 
apparent that reaching sufficient systemic exposure in patients 
was a key challenge because this drug substance is practically 
insoluble in an aqueous environment. Finally, solubility was 
improved by using a stabilized amorphous variant of vemu-
rafenib. This solid dispersion contains amorphous vemurafenib 
and hypromellose acetate succinate in which the drug sub-
stance is uniformly dispersed within the polymeric substrate. 
Currently, the approved daily dose of vemurafenib is 1920 mg 
(which equals twice daily 4 tablets containing 240 mg each) 
(Bollag et al., 2010; Shah et al., 2013). Because reaching suf-
ficient bioavailability is also a key challenge in animal studies 
with vemurafenib, we performed our experiments with both 
crystalline and stabilized amorphous material in order to test 
different conditions. In addition, a pharmacokinetic profile was 
established within the same mouse strain in order to support 
comparisons with published exposure data from both nonclini-
cal safety studies in animals and human clinical trials.
MATERIALS ANd METhodS
Test Compounds and Positive and Negative Control Items
For most animal studies, amorphous vemurafenib was used, which was 
commercially available as ZELBORAF tablets (240 mg/tablet; Roche, Basel, 
Switzerland). Prior to immediate dosing, the tablets were finely grinded with 
a pestle and a mortar. An appropriate amount of aqueous carboxymethylcellu-
lose (CMC) 0.5% was added to form a fine suspension (final dosage volume of 
20 ml/kg), which was sonicated without heating for 5 min and shaken/vortexed. 
The vehicle, CMC 0.5%, was used as control.
In addition, in-house synthesized vemurafenib was used, mainly for experi-
ments requiring solutions (eg, recording of UV-vis spectra, in vitro 3T3 phototox-
icity test). This material was assumed to be composed of crystalline forms, which 
are obtained from chemical synthesis if no special precautions are taken. Identity 
was confirmed based on 1H-NMR, LC-MS, and UPLC. The obtained data are in 
agreement with the known structure of vemurafenib. Purity was assessed using 
UPLC demonstrating 98% content with ethyl acetate as major remaining impurity.
Sparfloxacin and 8-methoxypsoralene (8-MOP), used as positive control 
reference compounds, were obtained from Sigma-Aldrich (Buchs, Switzerland) 
with at least 98% purity and available certificates of analysis.
UV-Visible Light Absorption Spectra
Light absorption spectra in the UV-visible range were recorded on a Cary 
300 spectrophotometer (Varian Australia Pty Ltd, Mulgrave, Australia) using 
UV-transparent quartz glass cuvettes (1 cm path length). Substances were dis-
solved in methanol applying individual solvent-specific baseline correction.
For each peak, the molar extinction coefficient (ε or MEC) was calculated: 
ε = ⋅A c l/( ) , A: absorbance, c: concentration of the solution in methanol, l: 
path length (cuvette).
In Vitro 3T3 Neutral Red Uptake Phototoxicity Test
The Balb/c mouse fibroblast cell line 3T3.A31 was obtained from the 
European Collection of Cell Cultures (ECACC, no. 86110401, at passage 82), 
United Kingdom. Cells were cultivated in Dulbecco’s Modified Eagle Medium 
(with phenol red) containing 10% fetal calf serum, 1% glutamine, and 1% peni-
cillin/streptomycin. The assay was performed in accordance with OECD Testing 
Guideline 432 (OECD, 2004). Briefly, 24 h after seeding the mouse fibroblast 
cells into 96-well plates, the medium was removed, and the cells were treated 
with different concentrations of the test compound for 1 h using Hank’s Buffered 
Salt Solution (HBSS) without phenol red as medium replacement. Subsequently, 
these cells were irradiated (+Irr) with simulated sun light (SOL 500 H1, Dr. 
Hönle GmbH, Gräfelfing, Germany) with a main spectral output from 320 until 
beyond 700 nm. The integrated H1 filter system attenuated the highly cytotoxic 
UVB range to a level that was tolerated by the cell culture as suggested by the 
mentioned guideline. (Fig. 1) The polystyrene lids were on the 96-well plates 
during light exposure. Calibration was performed through the lids as well. In 
parallel, an identically prepared 96-well plate was kept in the dark (−Irr), serv-
ing as control. UVA irradiance was measured by a UVA meter (Dr. Hönle AG) 
with spectral sensitivity in the range from 320 to 400 nm and a measuring range 
between 0 and 199.9 mW/cm2. The applied intensity was 1.67 mW/cm2, result-
ing in a total UVA dose of 5 J/cm2 after 50 min of irradiation. The related UVB 
exposure (calculated from the spectral irradiance of the light source) was around 
15 mJ/cm2. After irradiation, the HBSS buffer was replaced by fresh medium. 
Cell viability was determined 24 h later using neutral red as the vital dye, which 
was measured after incubation and extraction at 540 nm. The Photo-Irritation-
Factor (PIF) was calculated according to OECD TG 432 using the following 
equation: PIF IC Irr IC Irr5 5= +0 0( ) / ( ).−
Animal Experiments
Animal Husbandry
Female BALB/C mice aged of about 8 weeks at the start of the experiment, 
purchased from Charles River (L’Arbresle, France), were acclimatized for 
around 1 week. The experiments were performed in conformity with the Swiss 
Animal Welfare Law and in accordance with internal SOPs and guidelines for 
care and use of laboratory animals. Animals had ad libitum access to pelleted 
standard rodent diet and tap water from the domestic supply and were kept in an 
air-conditioned animal room under periodic bacteriological control, at 22°C ± 
2°C with monitored 30%–80% humidity, a 12-h light/dark cycle, and background 
radio coordinated with light hours.
Irradiation Conditions for Animal Experiments
During irradiation, mice were kept in specific cages allowing only for 
lateral movements and ensuring a uniform irradiation of their back and ears. 
Nonirradiated animals were kept in their housing cages under standard room 
light. For irradiation, a sun light simulator (Psorisan 900 H1, Dr. Hönle GmbH) 
was used showing a main spectral output from 320 until beyond 590 nm. The 
integrated H1 filter system attenuated the highly cytotoxic UVB range to a 
level that was tolerated by the animals. UVA irradiance was measured by a 
UV-radiometer (Dr. Hönle GmbH) with a spectral sensitivity in a range from 
320 to 400 nm and a measuring range between 0 and 199.9 mW/cm2. Typically, 
the applied intensity was 4.8 mW/cm2 at a distance of 50 cm. Irradiation was 
normalized to a dose of 10 J/cm2 UVA, which was typically achieved after 
35 min of light exposure. The related UVB exposure (calculated from the spec-
tral irradiance of the light source) was around 30 mJ/cm2. External calibration 
of the equipment was performed by Opto.cal GmbH (Movelier, Switzerland), 
which is a calibration laboratory accredited by the Swiss Accreditation Service.
Treatment Protocols and Endpoints
Oral UV-LLNA in BALB/c mice.  Studies A, B, and C: On 3 consecutive 
days, 6 mice/group were treated orally with the test compound (see Table 1 and 
Fig. 2 for details) dissolved in 0.5% aqueous CMC or with vehicle. Two hours 
after each treatment, mice from the groups “with UV” were irradiated.
Study D: On 3 consecutive days, 6 mice/group were treated orally with 350 
or 450 mg/kg of the amorphous form of vemurafenib. Mice from the 350 mg/kg 
“with UV” group were irradiated 2 h after each treatment, whereas mice from 
group 450 mg/kg “with UV” were irradiated 2 h after last treatment only on day 3.
Measurement of LLNA endpoints was done as described before (Ulrich 
et al., 2001): 24 h after the last irradiation, mice were sacrificed using carbon 
dioxide asphyxiation. Circular biopsies (0.5 cm2) from the apical area of each 
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ear were excised using a disposable punch and weighed as pairs on an ana-
lytical scale. Lymph node weights were obtained from lymph node pairs taken 
from individual animals and weighed using analytical scales. For the determi-
nation of individual lymph node cell counts, single-cell suspensions from the 
lymph node pairs from individual animals were prepared by mechanical tissue 
disaggregation through a sterile stainless steel gauze in 1 ml PBS (Ca2+/Mg2+ 
free) containing 0.5% bovine serum albumin. Individual cell counts were deter-
mined in a cell counter (CASYTTC cell counter, Schärfe System, Reutlingen, 
Germany) gating on a particle diameter above 4.88 μm.
Time profile of erythema and edema formation after irradiation.  Study 
E: On 3 consecutive days, 6 mice/group were treated orally with 350 mg/kg of 
the amorphous form of vemurafenib or with vehicle. Mice were irradiated 2 h 
after each treatment and sacrificed at 1, 2, 3, 4, and 6 h after light exposure on 
day 3. Circular biopsies (0.5 cm2) from the apical area of each ear were excised 
using a disposable punch and weighed as pairs on analytical scales.
Pharmacokinetic profile of vemurafenib in BALB/c mice.  On 3 consecu-
tive days, 6 mice/group were treated orally with a suspension of the amorphous 
form of vemurafenib. Blood samples from 3 animals per time point per group 
were collected from the vena saphena 1, 2, 4, and 7 h postdosing; blood speci-
mens from 6 mice per time point per group were collected from terminal heart 
puncture at 24 h after treatment on day 1 for animals from group 1, on day 2 for 
animals from group 2, and on day 3 for animals from group 3. Plasma was pre-
pared from blood specimens and stored on ice water until all plasma specimens 
were prepared. Specimens from all animals were analyzed. Twenty-four hours 
after the administration on day 1, 2, and 3, mice were sacrificed using carbon 
dioxide asphyxiation. Circular biopsies (= 0.5 cm2) from the apical area of each 
ear were excised using a disposable punch and weighed as pairs on an analytical 
scale. They were snap-frozen in liquid nitrogen and stored in a deep freezer at 
−70°C or below. Determination of vemurafenib in mouse plasma was performed 
by protein precipitation followed by LC-MS/MS using electrospray ionization 
in positive mode. The ear samples were homogenized with 9 volume equivalents 
of acetonitrile/water and then processed and analyzed like the plasma samples.
Statistical Analysis
For all statistical calculations, SigmaPlot for Windows (version 11.0) was 
used. A one-way ANOVA was used as the statistical method (Glantz, 1992). 
A normality test was performed to assure that the specimens were drawn from 
a normal population (significance level = 0.01). The equal variance test was 
used to check the assumption that the sample was drawn from populations with 
the same variance (significance level = 0.01). In case of significant results of 
the one-way ANOVA, multiple comparisons were performed with the Student-
Newman-Keuls test. If the normality test and/or the equal variance test gave 
p values < .01, a suitable transformation (log, square root) was applied; if the 
normality test and/or equal variance test still gave p values < .01, the nonpara-
metric Kruskal-Wallis test was used, and multiple comparisons for the ranks 
of the original observations were performed. The confidence interval for the 
difference of the means was set to 95% (α= .05).
RESULTS
UV-Visible Light Absorption Spectra
UV-visible spectra of vemurafenib and the reference 
compounds sparfloxacin and 8-methoxy psoralene were 
recorded from 290 to 700 nm, which is the spectral region 
relevant for photosafety assessment (sun light) (Table  2). 
Vemurafenib shows absorption mainly in the UVB (peak 
at 305 nm) and the short UVA region. Importantly, above 
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FIg. 1. Normalized UV-visible light absorption spectra of Vemu (dashed), SFX (solid), and 8-MOP (dotted) recorded at concentrations of 50 or 100µM in 
methanol. For comparison, the spectral intensity of the light sources used in this study are shown as overlap (SOL500, dashed gray; Psorisan900, solid grey). 
Abbreviations: 8-MOP, 8-methoxypsoralene; SFX, sparfloxacin; Vemu, vemurafenib.
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350 nm, no relevant absorption is observed. In comparison, 
8-MOP shows a similar absorption profile (peak at 299 nm), 
but absorption extends into the long UVA region up to 
380 nm. Sparfloxacin shows an additional peak (375 nm) in 
the long UVA, and absorption extends into the visible region 
up to 440 nm. For comparison, an overlay of these absorp-
tion spectra with the spectral irradiance of the light sources 
(in vitro: SOL500/H1 filter, in vivo: Psorisan900/H1 filter) is 
shown up to 600 nm in Figure 1. It should be noted that the 
obvious absorption of all 3 compounds in the UVB range is 
a common phenomenon among the majority of low molecu-
lar weight drug substances. However, for oral drugs, pho-
tosafety assessment is mainly focusing on UVA and visible 
light as these wavelengths are penetrating sufficiently into 
skin (ICH S10, 2013).
In Vitro Phototoxicity Test Results
The in vitro 3T3 NRU phototoxicity test measures cyto-
toxicity profiles in the presence or absence of simulated sun 
light using neutral red as vital dye. This assay is based on 
the calculation of the PIF, which represents the ratio of the 
IC
50
 values obtained with (+Irr) or without (−Irr) irradia-
tion. According to the respective OECD Testing Guideline 
432, compounds showing a PIF value above 5 (which equals 
a 5-fold shift of the IC
50
 value toward lower concentrations) 
are considered to be phototoxic. Vemurafenib (Table  2) was 
insoluble in cell culture buffer at concentrations higher than 
1.5 μg/ml, without showing significant cytotoxicity up to this 
concentration. However, in the presence of simulated sun 
light, a defined cytotoxicity profile was obtained (IC
50
 value of 
0.052 µg/ml). The resulting PIF value was 29 (using the solu-
bility limit of 1.5 µg/ml because no IC
50
 was obtained in the 
absence of irradiation), indicating that vemurafenib was clearly 
phototoxic in vitro to cultured cells. In addition, in vitro pho-
totoxicity results for sparfloxacin and 8-MOP are shown. PIF 
values for both compounds are limited by solubility as well. 
However, achieved concentrations were significantly higher, 
which resulted in much higher PIF values. Under these condi-
tions, the extremely low IC
50
 value of vemurafenib (0.052 µg/
ml) illustrates the potent inherent photoreactivity while the 
TABLE 1
Skin Irritation and Lymph Node (LN) Activation Induced by Vemurafenib (Vemu) Using Crystalline (crystal) and Amorphous  
Material (amorph)
Study
Ear Weights LN Weights LN Cell Count Erythema After 
UV Exposure 
(day 1/2/3)Mean (mg) SD Mean (mg) SD Mean (× 106) SD
A Sparfloxacin 100 mg/kg 19.26 0.58 4.44 0.52 8.11 1.66 —
Sparfloxacin 100 mg/kg UV 30.72*** 1.63 9.45*** 1.11 20.60*** 2.37 +/+/+
B Vehicle CMC 0.5% 24.55 1.54 5.99 0.97 9.96 2.24 —
Vemu crystal 20 mg/kg 20.03 0.62 5.99 0.99 11.78 1.66 —
Vemu crystal 20 mg/kg UV 20.87 0.86 5.18 0.91 9.77 2.86 −/−/−
Vemu crystal 100 mg/kg 20.62 0.57 5.48 0.79 10.19 1.50 —
Vemu crystal 100 mg/kg UV 20.69 0.68 6.51 0.79 11.99 1.01 −/−/−
Vemu crystal 350 mg/kg 20.98 0.38 5.90 1.12 11.86 2.75 —
Vemu crystal 350 mg/kg UV 21.25 0.6 6.11 0.69 11.95 1.84 −/−/−
C Vehicle CMC 0.5% 20.33 0.6 4.23 0.41 5.85 0.42 —
Vemu amorph 100 mg/kg 21.41 0.89 4.61 0.41 6.18 0.65 —
Vemu amorph 100 mg/kg UV 21.73 0.49 4.85 0.27 7.48 1.13 −/−/−
Vemu amorph 450 mg/kg 20.66 0.46 4.58 0.33 7.68 0.87 —
Vemu amorph 450 mg/kg UV 22.02 0.36 4.63 0.77 7.56 1.40 −/−/+
Vemu amorph 800 mg/kg 20.65 1.04 4.50 0.77 7.53 1.98 —
Vemu amorph 800 mg/kg UV 22.13 0.95 4.97 1.14 9.28 1.23 −/−/+
D Vemu amorph 350 mg/kg 21.12 0.40 5.07 0.33 5.72 0.59 —
Vemu amorph 350 mg/kg UV 21.11 0.46 5.69 0.94 6.58 1.08 −/−/+
Vemu amorph 450 mg/kg UV 
(UV on day 3 only)
20.70 0.39 5.35 1.12 6.81 1.50 −/−/+
E Vehicle CMC 0.5% 21.57 0.84 — — — — —
Vemu amorph 350 mg/kg 6 h 21.43 0.94 — — — — —
Vemu amorph 350 mg/kg UV 1 h 23.55** 0.71 — — — — −/−/+
Vemu amorph 350 mg/kg UV 2 h 23.48** 0.77 — — — — −/−/+
Vemu amorph 350 mg/kg UV 3 h 24.00*** 0.84 — — — — −/−/+
Vemu amorph 350 mg/kg UV 4 h 23.82** 0.83 — — — — −/−/+
Vemu amorph 350 mg/kg UV 6 h 24.31*** 1.25 — — — — −/−/+
Note. Six female Balb/c mice per group were treated orally on 3 consecutive days by gavage. Mean ear weights were obtained 1 day after the last exposure 
using the weights of circular pieces (0.5 cm2) punched from the apical area of 1 ear. Mean LN weights were derived from pairs of auricular LN from an individual 
animal, and mean LN cell count values represent the corresponding total cellularity of the LN. **0.1% < p < 1%, ***p < 0.1%, versus corresponding dose control. 
Data of the positive control, sparfloxacin, are displayed to illustrate the expected responses for each endpoint.
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solubility-limited PIF value of 29 is likely an underestimate of 
the true phototoxic potential.
Oral UV-LLNA
Data obtained with the positive control sparfloxacin are dis-
played in Table 1 (study A) to illustrate the expected responses 
for each endpoint. After oral administration of sparfloxacin 
(100 mg/kg), redness of the ears (erythema) was observed after 
each irradiation. At the time of necropsy, increased ear weight 
(edema) and a proliferation response in the ear-draining auricu-
lar lymph nodes were seen.
For vemurafenib (Fig. 2), the maximum tolerated dose (MTD) 
was established at 800 mg/kg in a dose-finding experiment 
using individual animals. Clinical symptoms were monitored 
during the dose-finding experiment, which started at a dose of 
2000 mg/kg body weight/day using amorphous material (finely 
grinded tablets). Following the first administration, reduced 
activity, piloerection, and hunched posture were observed dur-
ing the initial 5 h. In concordance with Mackay et al. (1992), 
1200 mg/kg was used as the next lower dose. Similar symp-
toms, although less pronounced, were observed allowing for 
additional irradiation after treatment. During the second and 
third day of treatment, erythema at the ear skin was observed. 
The next lower dose, 800 mg/kg, was well tolerated by mice 
for 3 days (apart from the irradiation-dependent erythema on 
day 3) and, therefore, was regarded as the MTD for amorphous 
vemurafenib to be considered in subsequent studies.
The oral UV-LLNA with vemurafenib was performed with 
doses of 20, 100, and 350 mg/kg of crystalline material and 
with doses of 100, 350, 450, and 800 mg/kg of amorphous 
material (Table 1, respectively, studies B, C, and D). After oral 
administration of crystalline vemurafenib, no clinical signs 
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and no redness of the ears were observed, and the ear-drain-
ing lymph nodes showed no proliferation response. After oral 
administration of amorphous vemurafenib, signs of phototox-
icity (erythema) appeared on day 3 directly after UV exposure 
at doses of 350, 450, and 800 mg/kg, but not at 100 mg/kg; this 
effect disappeared within the next 15 h. In addition, a less pro-
nounced erythema was already apparent after irradiation on day 
3 at the dose level of 800 mg/kg. However, at time of necropsy, 
the mice did not show a UV-dependent increase in ear weight 
at any dose. The ear-draining lymph nodes showed no prolif-
eration response at any dose. Based on the evident erythema 
reaction, 350 mg/kg was considered to be the lowest observable 
adverse effect level (LOAEL), whereas 100 mg/kg may be the 
no observable adverse effect level (NOAEL).
An alternative design of the UV-LLNA was used at a dose 
level of 450 mg/kg with the amorphous form in order to 
address the relevance of daily versus single irradiation (Study 
D). Mice were administrated 3 consecutive days with vemu-
rafenib but exposed to simulated sun light only on day 3. Signs 
of phototoxicity appeared on day 3 directly after UV exposure 
although the ear reddening was reduced compared with the 
results obtained with the standard study design. As before, no 
ear weight increase and no proliferation response of the ear-
draining lymph nodes were seen at the time of necropsy. This 
result suggests that for vemurafenib, repeated administration is 
needed in this mouse model in order to induce increased light 
sensitivity of the skin. Furthermore, induction of lymph node 
reactions driven by acute ear skin inflammation (as seen, for 
instance, with sparfloxacin) starts on day 3 and would only 
become visible after an extension of the treatment protocol up 
to 5 days.
Time Profile of Erythema and Edema Formation After 
Irradiation
The time profile obtained on the last of 3 consecutive days 
with daily treatment (Study E, 350 mg/kg amorphous vemu-
rafenib followed by irradiation) is shown in Figure  3. Ear 
weights were significantly increased at 1, 2, 3, 4, and 6 h postir-
radiation compared with the control group, illustrating that a 
pronounced edema is formed at the same time at which the 
erythema can be observed. However, 24 h later (the standard 
sampling time point of the UV-LLNA), the ear weight increase 
after vemurafenib had already decreased to predose levels.
Pharmacokinetic Profile
Concentrations of vemurafenib found in mouse plasma over 
3 days were found to be similar (Fig. 4), ranging from 54 to 
193 µg/ml (C
min
, C
max
) on day 3. The time to reach the highest 
plasma concentration was between 2 and 4 h after the adminis-
tration irrespective of the day. The apparent half-life time was 
10–13 h, showing a slight decrease during treatment days. The 
amount of vemurafenib found in ear skin tended to decrease 
after repetitive administration and was about 2-fold lower com-
pared with plasma. Distinct accumulation was neither found in 
plasma nor in ear skin.
dISCUSSIoN ANd CoNCLUSIoN
From a chemical point of view, vemurafenib carries all fea-
tures of a clinically relevant phototoxic substance: (1) It does 
absorb sun light within UVB and UVA up to 350 nm; (2) it 
shows in vitro a significant phototoxic reaction in cell culture 
(proving photochemical reactivity), and (3) it contains a fun-
damental structural element (diaryl ketone or benzophenone 
chromophore) also seen in known clinically phototoxic drugs 
such as ketoprofen or amiodarone. However, it is important 
to remember that without sufficient distribution to sunlight-
exposed tissues, such compounds do not lead to clinically rel-
evant phototoxic reactions. Therefore, it is essential to confirm 
these in vitro findings in established animal models of photo-
toxicity as long as meaningful human phototoxicity data cannot 
be generated easily.
In our established in-house in vivo phototoxicity model (oral 
UV-LLNA in mice), we were able to demonstrate dose- and 
time-dependent phototoxicity of vemurafenib using commer-
cially available tablets (stabilized amorphous material). The 
lowest phototoxic dose was 350 mg/kg given for 3 consecu-
tive days followed by exposure to UV-visible irradiation at a 
UVA-normalized dose of 10 J/cm2 (related blood plasma levels 
of vemurafenib on day 3, C
max
: 193 µg/ml, C
min
: 54 µg/ml). In 
comparison, pure vemurafenib, which forms easily crystalline 
variants and is known to have poor bioavailability, was tested 
at 350 mg/kg. Indeed, no signs of phototoxicity could be seen, 
which emphasizes the importance of adequate formulations 
and confirmed systemic exposure (either measured in blood or 
tissue or indirectly by clinical signs).
TABLE 2
Summary of Spectrophotometric and In Vitro Phototoxicity data for Vemurafenib and for the Reference Compounds  
Sparfloxacin and 8-Methoxypsoralene
Compound MEC l/(mol·cm) Precipitation (µg/ml) IC
50
 (−Irr) (µg/ml) IC
50
 (+Irr) (µg/ml) PIF
Vemurafenib 22 800 (305 nm) > 1.50 — 0.052 > 29
Sparfloxacin 33 600 (305 nm) > 500 — 6.16 > 82
8-Methoxy psoralene 10 700 (299 nm) > 100 — 0.22 > 457
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Interestingly, initial studies performed as part of the nonclini-
cal development of vemurafenib could not confirm any phototox-
icity in vivo (for details, see CHMP review, 2011, FDA review, 
2011). At that time, hairless female rats (Ico:OFA-hr/hr) were 
treated daily for 7 days at dose levels of 30, 150, and 450 mg/kg 
using stabilized amorphous material comparable to that used later 
in commercial tablets. Although not reported for the hairless rat, 
sufficient systemic exposure can be assumed based on toxikoki-
netic data available from general toxicity studies (26-week tox-
icity study, female Crl:CD(SD) rats, daily dose of 450 mg/kg: 
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FIg. 3. Time-dependent edema reaction in mouse ears. A significant, time-dependent increase (up to 13%) of the ear weights (punch-out biopsies) within 
6 h post-UV exposure is seen. Ear weight at 24 h from Study D. *Vemurafenib-treated groups (350 mg/kg), comparison of UV exposed versus non-UV exposed. 
Student’s t test (unpaired), significance levels: **p < .01), ***p < .001.
FIg. 4. Mean concentrations of vemurafenib versus time in mouse plasma. Six mice per group were treated orally with a suspension of amorphous vemu-
rafenib on up to 3 consecutive days. Blood samples from 3 animals per time point per group were collected from the vena saphena at 1, 2, 4, and 7 h postdose. 
In addition, from all animals of a group (1 per day), terminal samples at 24 h were taken from heart puncture. At the same time, point ear samples were taken 
(punch-out biopsies).
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C
max
 at day 1: 70 µg/ml, C
max
 at day 91: 115 µg/ml, converted 
from reported molar concentrations: 143.1 and 234.7µM, respec-
tively). Irradiation of the treated hairless rats was performed on 
the last day of treatment starting 90 min after last administration 
of vemurafenib with UVA doses ranging from 5 to 35 J/cm2. 
The light source had apparently the characteristics of fluorescent 
tubes with a reported maximal spectral output range from 350 
to 400 nm and a peak at 370 nm (Fig. 1). In comparison to the 
light absorption spectrum of vemurafenib, it is becoming evident 
that there is no spectral overlap between this original light source 
used during development of vemurafenib and the test compound. 
This fact alone may fully explain the negative results of this ear-
lier study in hairless rats because duration of treatment and expo-
sure to both vemurafenib and the formal UVA dose (limited to 
350–400 nm) was clearly exceeding the conditions we have used 
in our studies in mice reported above.
In patients, efficacious dose levels have been reported to show 
average C
max
 values around 60 µg/ml (CHMP review, 960 mg 
b.i.d., day 15), which is comparable to the exposure reached in 
mice at 350 mg/kg and in rats at 450 mg/kg. However, human 
PK profiles differ significantly from those seen in preclinical 
animal species. Particularly half-life in blood plasma appears 
to be several-fold longer in men (57 h), which suggests that 
a steady state is reached only after many days of treatment. 
Nevertheless, it should be noted that phototoxicity in vivo (both 
animal and human) is driven by the presence of photoreac-
tive molecules in light-exposed tissues. Therefore, compari-
son of achieved peak concentrations (C
max
)—even at different 
T
max
—remains the most appropriate exposure assessment (see 
also ICH S10, 2013), whereas AUC-based evaluations are of 
limited value.
So far, human phototoxicity data have only been reported from 
patient populations (see earlier). Two groups (Dummer et  al., 
2012; Gelot et al., 2013) have reported follow-on investigations 
for individual patients. In summary, clinical representation of 
vemurafenib-induced phototoxicity was described as a quickly 
occurring erythema accompanied by an edema and in some cases 
a burning sensation during light exposure and was apparently 
UVA dependent. As described by Ferguson (2002), this clinical 
presentation is typical for direct photochemical mechanisms of 
phototoxicity. Gerlot et  al. speculated that the observed UVA 
dependency could be explained by increased systemic porphyrin 
levels. However, the authors did not discuss the known intrin-
sic photoreactivity of vemurafenib, which is—as confirmed by 
our own results—indeed UVA driven (UV-vis spectrum, in vitro 
and in vivo phototoxicity tests) and can easily explain the clinical 
reactions. The quick onset of edema formation in mice (Fig. 3) 
resembles the acute clinical reactions in men. Although vemu-
rafenib does not show typical signs of accumulation or reten-
tion in skin (neither in animals nor in men), phototoxicity may 
be linked to steady-state conditions. In our in vivo studies, an 
irradiation-induced skin reaction at the lowest effective dose 
level (350 mg/kg) became apparent only after 3 consecutive days 
of dosing. However, at higher dose levels, these skin reactions 
started already on day 2. Currently, there is no data providing 
further insight. Assuming that vemurafenib molecules represent 
the photoreactive species (rather than endogenous molecules as 
discussed above), there may be slower but critical redistribution 
processes (within skin, within cells), which are ultimately driv-
ing susceptibility of skin to UVA light.
In conclusion, our investigations on the kinase inhibitor 
vemurafenib confirm a nonclinical safety profile, which is con-
sistent with the clinical signs of phototoxicity seen in many 
treated patients. Furthermore, these results highlight once 
again the impact of carefully designed in vivo phototoxicity 
studies. It is apparent that duration of treatment and timing of 
irradiation are key parameters to ensure an appropriate sensi-
tivity. These elements of the study design should be supported 
by relevant pharmacokinetic data. The common perception 
is that if a compound presents an identical pharmacokinetic 
profile over several days, a single-treatment/single-irradiation 
design is appropriate as it would not be affected by an accu-
mulation of the compound into the skin. However, this case 
clearly shows that even for compounds without apparent over-
proportional distribution to skin, a single-treatment/single-
irradiation design can be inappropriate. Finally, it is evident 
that appropriate irradiation conditions are crucial. The more 
general use of “solar simulator” light sources covering at least 
the full range of UVA and visible light should be considered 
state of the art.
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